Data Published in Journal Critical Care Explorations Evaluates Cytovale’s IntelliSep Test in Triaging Patients with High Risk of Sepsis, Morbidity and Mortality

SAN FRANCISCO--(BUSINESS WIRE)--Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune-mediated diseases, today announced the first enrollment in a clinical trial of the Cytovale system and IntelliSep test to aid in the rapid assessment of potential for sepsis in the emergency department (ED).

SAN FRANCISCO--(BUSINESS WIRE)--Cytovale, a medical diagnostics company focused on providing a faster, more insightful way to diagnose fast-moving and immune mediated diseases, today announced the publication of a study in the peer-reviewed journal PLOS ONE evaluating its IntelliSep test in the rapid diagnosis of sepsis in the hospital emergency department. Data from the study, “Development and validation of a cellular host response test as an early diagnostic for sepsis,” showed that Cytovale’s test has the potential to provide clinically actionable performance in distinguishing potentially septic patients.

Cytovale garners an AACC Academy’s Distinguished Abstract Award for study of its IntelliSep sepsis test, which utilizes routine blood draw samples, requiring minimal operator handling, and achieves a blood-to-answer turnaround time of less than 10 minutes

Cytovale Inc. will expand its partnership with the Biomedical Advanced Research and Development Authority, or BARDA, to examine the use of Cytovale’s Rapid Sepsis Diagnostic System for diagnosing sepsis in patients with potential respiratory infections, including COVID-19, according to a press release.

Hollis O’Neal, MD, pulmonary-critical care expert, Our Lady of the Lake, and the national primary investigator for the Cytovale early sepsis detection system, discusses sepsis and COVID-19 and provides an overview of his pilot study.

The Biomedical Advanced Research and Development Authority (BARDA) has hit an organization with Cytovale to build up a quick demonstrative framework for sepsis as a major aspect of the COVID-19 pandemic reaction.

Cytovale has received $3.8 million from HHS’ Biomedical Advanced Research and Development Authority (BARDA) for a study of its rapid-sepsis test for COVID-19 patients.

The Biomedical Advanced Research and Development Authority (BARDA) has struck a partnership with Cytovale to develop a rapid diagnostic system for sepsis as part of the COVID-19 pandemic response.

Expansion of BARDA funding will help fund Cytovale pilot study for innovative rapid sepsis diagnostic system that delivers results in under 10 minutes

Medical cell technology company Cytovale is set to conduct a pilot study of its rapid diagnostic test for sepsis in patients with suspected SARS-CoV-2 and other respiratory infections. The study is being carried out with support from the U.S. Biomedical Advanced Research and Development Authority (BARDA).

Medical technology company Cytovale announced Thursday it has received an additional $3.8 million to fund a pilot study for its rapid sepsis diagnostic system for patients with respiratory infections.